Salem Investment Counselors’s GSK GSK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$124K Sell
2,348
-8
-0.3% -$423 ﹤0.01% 470
2026
Q1
$131K Buy
+2,356
New +$128K ﹤0.01% 439
2025
Q4
Sell
-2,348
Closed -$102K 697
2025
Q3
$102K Hold
2,348
﹤0.01% 464
2025
Q2
$91.2K Hold
2,348
﹤0.01% 470
2025
Q1
$91.9K Buy
2,348
+500
+27% +$18.3K ﹤0.01% 468
2024
Q4
$63.2K Sell
1,848
-20
-1% -$720 ﹤0.01% 537
2024
Q3
$77.1K Sell
1,868
-140
-7% -$5.73K ﹤0.01% 497
2024
Q2
$78.1K Hold
2,008
﹤0.01% 481
2024
Q1
$86.9K Buy
2,008
+80
+4% +$3.3K ﹤0.01% 470
2023
Q4
$72.1K Buy
1,928
+40
+2% +$1.44K ﹤0.01% 489
2023
Q3
$69.1K Hold
1,888
﹤0.01% 474
2023
Q2
$68K Hold
1,888
﹤0.01% 482
2023
Q1
$67.8K Sell
1,888
-300
-14% -$10.5K ﹤0.01% 481
2022
Q4
$78.6K Sell
2,188
-2,818
-56% -$93.9K ﹤0.01% 450
2022
Q3
$149K Sell
5,006
-233
-4% -$8.83K 0.01% 345
2022
Q2
$287K Buy
5,239
+533
+11% +$29.4K 0.01% 292
2022
Q1
$256K Hold
4,706
0.01% 310
2021
Q4
$259K Sell
4,706
-160
-3% -$8.32K 0.01% 338
2021
Q3
$232K Buy
4,866
+160
+3% +$8.04K 0.01% 325
2021
Q2
$234K Hold
4,706
0.01% 306
2021
Q1
$210K Hold
4,706
0.01% 277
2020
Q4
$216K Sell
4,706
-80
-2% -$3.67K 0.01% 272
2020
Q3
$225K Buy
4,786
+160
+3% +$8.02K 0.02% 240
2020
Q2
$236K Hold
4,626
0.02% 227
2020
Q1
$219K Hold
4,626
0.02% 223
2019
Q4
$272K Hold
4,626
0.02% 226
2019
Q3
$247K Hold
4,626
0.02% 230
2019
Q2
$231K Sell
4,626
-240
-5% -$12K 0.02% 239
2019
Q1
$244K Buy
4,866
+240
+5% +$12K 0.02% 182
2018
Q4
$221K Sell
4,626
-240
-5% -$11.8K 0.03% 177
2018
Q3
$244K Hold
4,866
0.02% 182
2018
Q2
$245K Hold
4,866
0.02% 184
2018
Q1
$237K Sell
4,866
-76
-2% -$3.54K 0.03% 183
2017
Q4
$219K Buy
4,942
+76
+2% +$3.51K 0.02% 188
2017
Q3
$249K Hold
4,866
0.03% 186
2017
Q2
$262K Hold
4,866
0.03% 193
2017
Q1
$255K Sell
4,866
-508
-9% -$25.8K 0.03% 222
2016
Q4
$259K Buy
+5,374
New +$265K 0.03% 221
2016
Q3
Sell
-4,877
Closed -$264K 532
2016
Q2
$264K Hold
4,877
0.03% 223
2016
Q1
$247K Hold
4,877
0.03% 225
2015
Q4
$246K Hold
4,877
0.03% 227
2015
Q3
$232K Hold
4,877
0.03% 239
2015
Q2
$254K Hold
4,877
0.03% 244
2015
Q1
$281K Hold
4,877
0.03% 242
2014
Q4
$261K Sell
4,877
-1,120
-19% -$62.7K 0.03% 237
2014
Q3
$345K Hold
5,997
0.04% 223
2014
Q2
$401K Sell
5,997
-16,320
-73% -$1.1M 0.05% 213
2014
Q1
$1.49M Hold
22,317
0.18% 118
2013
Q4
$1.49M Hold
22,317
0.19% 112
2013
Q3
$1.4M Sell
22,317
-3,520
-14% -$227K 0.19% 112
2013
Q2
$1.61M Buy
+25,837
New +$1.64M 0.23% 94

Other funds holding GSK

Salem Investment Counselors's GSK Position: Q2 2026 in Review

Salem Investment Counselors reduced its GSK (GSK) stake by 0.34% in Q2 2026, selling an estimated $423 and leaving 2,348 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #470.

Salem Investment Counselors first reported a position in GSK in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.61M in Q2 2013. 413 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Salem Investment Counselors held 2,348 shares of GSK worth $124K as of Q2 2026.
  • Salem Investment Counselors sold 8 GSK shares in Q2 2026, an estimated $423.
  • GSK made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #470 holding.
  • Salem Investment Counselors first reported a position in GSK in Q2 2013 and has held it in 51 quarters since.
  • Salem Investment Counselors's GSK position peaked at $1.61M in Q2 2013.
  • 413 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.